IBOV 166,708.04 ▼ 0.14% IPSA 11,101.37 ▲ 0.53% IPC MEX 64,152.21 ▼ 0.38% MERVAL 2,947,349 ▼ 1.77% COLCAP 2,452.46 ▲ 0.84% BVL PERÚ 58,104.31 ▲ 0.40% USD/BRL5.20▼ 0.48% USD/MXN17.03▲ 0.04% USD/CLP914.24▼ 0.09% USD/COP3,133▼ 0.03% USD/PEN3.36▼ 0.32% USD/ARS1,488▼ 0.02% USD/UYU40.33▲ 0.01% USD/PYG5,997▲ 0.22% USD/BOB11.50▼ 0.35% USD/DOP58.55▲ 0.17% USD/CRC446.12— 0.00% USD/GTQ7.62▼ 0.05% USD/HNL26.79— 0.00% USD/NIO36.62— 0.00% USD/VES770.61▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.73▲ 0.41% EUR/BRL6.02▼ 0.48% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 166,708.04 ▼ 0.14% IPSA 11,101.37 ▲ 0.53% IPC MEX 64,152.21 ▼ 0.38% MERVAL 2,947,349 ▼ 1.77% COLCAP 2,452.46 ▲ 0.84% BVL PERÚ 58,104.31 ▲ 0.40% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Monday, August 17, 2026

Brazil Covid-19

Covid-19 Pandemic Could Last Until 2022, Says Harvard Professor

By · May 29, 2020 · 3 min read

Daily Brief

The morning intel from across Latin America. Free.

By subscribing you agree to our privacy policy. We never share your email.

RIO DE JANEIRO, BRAZIL – For immunologist and Harvard professor Timothy Springer, the novel coronavirus pandemic is likely to last until next year and will likely continue for a period in 2022.

In an interview with EXAME, Springer said that “the current Covid-19 crisis is similar to a war and that it “will be even more severe than any we have seen this century, and it will probably last longer, possibly three years. “And it’s going to be particularly hard on underdeveloped countries,” Springer said.

For US Harvard immunologist and professor Timothy Springer, the novel coronavirus pandemic is likely to last until next year and will likely continue for a period in 2022.
Immunologist and professor Timothy Springer has a dire prediction for the world. (Photo internet reproduction)
One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →
RT
Ask Rio Times
This story and the bigger picture.
Open the full Ask Rio Times →

Worldwide, nearly six million people are infected with the disease and 357,929 have died, according to real-time monitoring from Johns Hopkins University. The United States is the epicenter of the virus, with 1,711,313 patients and 101,129 deaths. Brazil, a country that has seen a daily increase in the number of infections and deaths, ranks second with 25,598 dead and 411,821 sick, according to the latest data from the Ministry of Health.

To reach his projection, Springer relied on the Spanish flu epidemic, which happened in the end of World War I in 1918 and spread among army barracks, eventually leaving 50 million dead worldwide in the space of two years. “It was a terrible world epidemic and we lost the collective memory of how bad the virus was.

“In the United States, more people died from the flu in 1918, 1919, and 1920 than in all the US wars in the 1900s″, he explains. “And the same is true around the world. Many people died from the disease. And while we have had many memorials for those who died in the wars, we have none for those who died from the flu. And that has created a blind spot in our collective consciousness,” he says.

Springer is one of the investors in the American biotechnology company Moderna, which last week released successful tests of a potential vaccine against the virus. According to Forbes, the professor holds a 3.5 percent stake in the company, which he purchased with an initial investment of US$5 million in 2010.

Based on the total shares the company had in February, in the last balance disclosed, the professor would have almost 13 million shares. Thus, between the first investment and the shares in 2020, the yield was over 17,000 percent.

According to him, the vaccine should be ready “sometime in the fall” in the United States, a season that runs from September to November in the northern hemisphere. “Nevertheless, unfortunately, it will take another year for this vaccine to be available, because manufacturing will be limited,” he explains.

The Ebola vaccine, for instance, was approved two decades after studies on preventing the virus began and took five years to produce. The measles vaccine began to be studied in 1945 and was only produced in the 1960s – time periods that are not quite so optimistic from a social perspective, but rather from a scientific one.

For Springer, the only way to stop the virus from spreading until a vaccine is produced is social distancing. “Everyone should wear masks, because that protects not only the person wearing it, but also those around the person.

“Frequent hand washing, avoid touching one’s lips, nose, and eyes, because one’s hands will have come into contact with surfaces on which people with the virus may have touched. This has to be taken seriously,” he says.

Source: Exame

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.